-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 6044 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 6044 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
intraday looks pretty good. If they had the right news (as in anything else duh!) this could really pop. If it weren't going down...
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 6044 | From: Virginia | Registered: May 2006
| IP: Logged |
quote:Originally posted by IMAKEMONEY: BUYING BUYING BUYING,LOL,POP!!!
DAYTRADERS!! PHLEEEEEWY!!!
D
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 6044 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 6044 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
yah. I though .20 or so would be a good bounce. I was waiting it out though to see if it would drop lower. We'll see.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 6044 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
My server changed hands - i was out from before lunch and most of the afternoon! grrrr
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 6044 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Advanced Cell Technology's Chief Executive Officer Scheduled to Be Interviewed By Bloomberg Television Tonight
Nov 20, 2007 15:46:04 (ET)
LOS ANGELES, Nov 20, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that William M. Caldwell, IV, the company's Chief Executive Officer is scheduled to be interviewed today by Bloomberg Television at 6:15 p.m. eastern time. Mr. Caldwell is expected to discuss the Company's Retinal Program, as well as other corporate developments and issues surrounding the stem cell industry.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Media: Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 8878 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
quote:Originally posted by IMAKEMONEY: HMM, NEWS COMING?????
you da man IMAKE
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 6044 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Very nice. The news is all about stem cell. It should boost the whole sector imo. Thought it would do something for my NRGX for Parkinson’s and such. In time. Should speed things up considerably. These guys are trying to get (and somewhat succeeded) their name in the lime light to boost their research funding. Just poking their nose in the right places. Getting the word out that's for sure.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 6044 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
.295 trying to break through... can it do it!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 6044 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Nice finish. Short day Friday but could be exciting. Broke .3 Would have liked to see .31
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 6044 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
break out yes or no? Not much volume but looking for .31 then maybe a breakout.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 6044 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
imo they were sponging off someone elses news that was great for the sector but not immediatly great for ACTC - still years to go. Could see more on this next week.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 6044 | From: Virginia | Registered: May 2006
| IP: Logged |
NEW YORK, Nov 27, 2007 (BUSINESS WIRE) -- The New York Society of Security Analysts (NYSSA) will present the 11th Annual Biotech/Specialty Pharma Conference on December 11-12, 2007.
The Nasdaq and AMEX biotech stock indexes have been consistently on the rise year over year. Small- and mid-cap companies have driven the growth, but big biotech has lagged behind big pharma. Although biotech has fallen behind most major indexes, some analysts believe that a turnaround is imminent. Leaders of small- and micro-cap companies will reveal plans to develop new drugs, diagnostics, and delivery technologies.
The following companies are presenting on day one:
BioSante Pharmaceuticals, Inc. (AMEX: BPA); DURECT Corporation (DRRX, Trade ); EntreMed, Inc. (ENMD, Trade ); GammaCan International, Inc. (GCAN, Trade ); Heska Corporation (HSKA, Trade ); Hollis-Eden Pharmaceuticals, Inc. (HEPH, Trade ); NovaBay Pharmaceuticals, Inc. (NBY, Trade ); and The Quigley Corporation (QGLY, Trade ).
The following companies are presenting on day two:
Advanced Cell Technology (ACTC, Trade ); Alseres Pharmaceuticals, Inc. (ALSE, Trade ); Cyclacel Pharmaceuticals, Inc. (CYCC, Trade ); Emergent BioSolutions, Inc. (EBS, Trade ); Hemispherx Biopharma, Inc. (HEB, Trade ); Immtech Pharmaceuticals, Inc. (IMM, Trade ); Neuralstem, Inc. (CUR, Trade ); Ortec International, Inc. (OTCI, Trade ); and Transdel Pharmaceuticals, Inc. (TDLP, Trade ).
The conference will be held on December 11, 2007, 8:30 a.m. to 4:40 p.m., and December 12, 2007, 8:30 a.m. to 4:10 p.m. at NYSSA, 1177 Avenue of the Americas, 2nd Floor, NYC. Registration deadline is December 4, one day, $265 NYSSA members, $365 nonmembers; two days, $365 NYSSA members, $465 nonmembers. No charge for press with credentials. A complete agenda is available at http://www.nyssa.org/Biotech2007 .
About NYSSA
The New York Society of Security Analysts (NYSSA) is celebrating 70 years as a leading forum for the investment community. NYSSA's mission is to promote best practices and the highest professional and ethical standards in the industry. NYSSA is the largest of the more than 135 societies worldwide that make up CFA Institute, which has more than 90,000 members.
SOURCE: The New York Society of Security Analysts
NYSSA Dawn Cavalieri, 646-871-3420 press*nyssa.org
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 8878 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
NEW YORK, Nov 29, 2007 (BUSINESS WIRE) -- The New York Society of Security Analysts (NYSSA) will present the 11th Annual Biotech/Specialty Pharma Conference on December 11-12, 2007.
The Nasdaq and AMEX biotech stock indexes have been consistently on the rise year over year. Small- and mid-cap companies have driven the growth, but big biotech has lagged behind big pharma. Although biotech has fallen behind most major indexes, some analysts believe that a turnaround is imminent. Leaders of small- and micro-cap companies will reveal plans to develop new drugs, diagnostics, and delivery technologies.
New companies have been added to the agenda:
Chelsea Therapeutics (CHTP, Trade ); EpiCept Corporation (EPCT, Trade ); and YM BioSciences Inc. (YMI, Trade ).
The following companies are presenting on day one:
BioSante Pharmaceuticals, Inc. (BPAX, Trade ); Chelsea Therapeutics (CHTP, Trade ); DURECT Corporation (DRRX, Trade ); EntreMed, Inc. (ENMD, Trade ); Heska Corporation (HSKA, Trade ); Hollis-Eden Pharmaceuticals, Inc. (HEPH, Trade ); NovaBay Pharmaceuticals, Inc. (NBY, Trade ); The Quigley Corporation (QGLY, Trade ) and YM BioSciences Inc. (YMI, Trade ).
The following companies are presenting on day two:
Advanced Cell Technology (ACTC, Trade ); Alseres Pharmaceuticals, Inc. (ALSE, Trade ); Cyclacel Pharmaceuticals, Inc. (CYCC, Trade ); Emergent BioSolutions, Inc. (EBS, Trade ); EpiCept Corporation (EPCT, Trade ); Hemispherx Biopharma, Inc. (HEB, Trade ); Immtech Pharmaceuticals, Inc. (IMM, Trade ); Neuralstem, Inc. (CUR, Trade ); Ortec International, Inc. (OTCI, Trade ); and Transdel Pharmaceuticals, Inc. (TDLP, Trade ).
The conference will be held on December 11, 2007, 8:30 a.m. to 4:40 p.m., and December 12, 2007, 8:30 a.m. to 4:40 p.m. at NYSSA, 1177 Avenue of the Americas, 2nd Floor, NYC. Registration deadline is December 4, one day, $265 NYSSA members, $365 nonmembers; two days, $365 NYSSA members, $465 nonmembers. No charge for press with credentials.
The New York Society of Security Analysts (NYSSA) is celebrating 70 years as a leading forum for the investment community. NYSSA's mission is to promote best practices and the highest professional and ethical standards in the industry. NYSSA is the largest of the more than 135 societies worldwide that make up CFA Institute, which has more than 90,000 members.
SOURCE: The New York Society of Security Analysts
NYSSA Dawn Cavalieri, 646-871-3420 press*nyssa.org
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 8878 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
Related Quotes Sym. Price Chg. ACTC Trade News 0.215 0.001 Advanced Cell Technology Seeking International Partners for Its Therapeutic Programs
Dec 6, 2007 08:00:09 (ET)
LOS ANGELES, Dec 06, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) announced today that it is seeking international partners for each of its three lead therapeutic programs, including its Myoblast program for treating heart failure, its Retinal Pigment Epithelium program for treating degenerative retinal disease, and the Hemangioblast program for the treatment of blood and cardiovascular indications. The company is making significant progress in the development of each of these therapeutic programs within the United States.
Advanced Cell Technology has made a strategic decision to seek partners for each of these programs internationally, including regions such as Europe, the Middle East and Asia, as the company recognizes that there is strong interest in the field of stem cells worldwide. ACT has asked Burrill & Company, which it hired last year to advise on a number of strategic initiatives, to renew its focus on seeking international partners. Interested parties worldwide should contact Mr. William Caldwell, IV, Chairman and CEO of Advanced Cell Technology at 310-481-5124.
"We recognize that there is material interest in the stem cell and regenerative medicine field globally and will seek strong partners from the worldwide medical community to pursue our programs outside of the United States and complement the work we are doing at home. We are very pleased to continue our successful relationship with Burrill & Company and utilize their extensive global network to further these discussions," said Mr. William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the emerging field of regenerative medicine. The company operates facilities in California and Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
Chad Griffin Consulting, Inc. Jordan Markwith, 310-888-3523 or Investors: CEOcast, Inc. Andrew Hellman, 212-732-4300
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 8878 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
UBBFriend: Email this page to someone!
![[Eek!]](eek.gif)
![[Big Grin]](biggrin.gif)
![[Wink]](wink.gif)
![[Cool]](cool.gif)